Barrett's oesophagus

What is Barrett's oesophagus?

Barrett's oesophagus is a condition in which the normal squamous lining of the lower oesophagus is replaced by columnar epithelium resembling intestinal mucosa. This change is typically a consequence of chronic gastro-oesophageal reflux. It is considered a pre-malignant condition because it increases the risk of oesophageal adenocarcinoma.

Not everyone with reflux develops Barrett's oesophagus. When it is found, the focus shifts from symptom control alone to surveillance — periodic endoscopy with biopsy to detect early changes (dysplasia) that can be treated before cancer develops.

How it is diagnosed

Barrett's oesophagus is diagnosed at endoscopy. A gastroenterologist looks at the lower oesophagus and measures how far the columnar lining extends above the gastro-oesophageal junction. Biopsies are taken to confirm intestinal metaplasia.

• Long-segment Barrett's — columnar lining extending 3 cm or more above the junction.
• Short-segment Barrett's — columnar lining extending less than 3 cm.
• Short-segment Barrett's without intestinal metaplasia does not require surveillance once confirmed on two endoscopies.

Surveillance

NICE NG231 recommends that all patients with newly diagnosed Barrett's oesophagus should be offered a clinical consultation to discuss cancer risk, surveillance plans, and symptom control.

• Surveillance intervals depend on segment length and the presence of intestinal metaplasia:
  • Long-segment (≥3 cm): every 2–3 years
  • Short-segment (<3 cm) with intestinal metaplasia: every 3–5 years
• High-resolution white light endoscopy with the Seattle biopsy protocol is recommended for surveillance.
• Risk stratification should consider age, sex, family history of oesophageal cancer, and smoking history.

Do not apply a one-size-fits-all schedule. Your gastroenterology team will set an interval based on your endoscopy and biopsy results.

Common symptoms

Barrett's oesophagus itself does not usually cause symptoms that are distinct from the reflux that preceded it. Many people are diagnosed during investigation for:

• Long-standing heartburn or acid reflux
• Regurgitation
• Dysphagia (difficulty swallowing)
• Upper abdominal discomfort

Red-flag symptoms requiring urgent assessment include vomiting blood, black/tarry stools, unintentional weight loss, progressive dysphagia, and severe sudden abdominal or chest pain. These are not specific to Barrett's but should always be assessed promptly.

Common patterns

• More common in males and in people with a long history of reflux.
• Risk increases with age, smoking, and central obesity.
• Family history of oesophageal cancer may influence risk stratification and surveillance intensity.
• Many people with Barrett's oesophagus never progress to cancer.

Overlapping conditions

Barrett's oesophagus overlaps with several conditions already covered on this site:

• GORD / reflux — All Barrett's oesophagus is preceded by chronic reflux. Acid suppression with PPIs remains a cornerstone of symptom control. The distinction is that Barrett's involves a histological change and requires surveillance. Read about GORD.
• Functional dyspepsia — Overlapping upper-GI symptoms, but Barrett's is a structural/histological diagnosis confirmed at endoscopy. Read about functional dyspepsia.
• Stomach ulcer and gastritis — Acid-related but anatomically distinct (oesophageal vs gastric). They are managed with different pathways and do not require the same surveillance.

Approaches people discuss

These are not treatment plans. They are approaches that people and clinicians discuss in the context of Barrett's oesophagus.

• Established Acid suppression with PPIs to control reflux symptoms and reduce ongoing acid damage. This is a standard part of care, not a cure for Barrett's. Sources: NICE NG231; BSG/ESGE.
• Established Endoscopic surveillance at intervals set by your gastroenterology team based on segment length and biopsy findings. Sources: NICE NG231 1.3.2–1.3.3.
• Established Endoscopic resection for suspected stage 1 oesophageal adenocarcinoma, offered as part of specialist staging. Sources: NICE NG231 1.4.1.
• Established Smoking cessation and weight management as supportive measures that reduce risk. Sources: NICE NG231 1.3.4.
• Established Aspirin should not be offered to people with Barrett's oesophagus to prevent progression to dysplasia or cancer. NICE NG231 explicitly advises against this. Sources: NICE NG231 1.2.2.

Community insights

These are patterns people report, not outcomes we can measure:

• The word "pre-cancerous" can cause anxiety that is out of proportion to the low annual risk. Many people find reassurance in understanding the surveillance plan.
• Adapting to a surveillance rhythm — endoscopy every few years — becomes part of long-term health maintenance.
• Some people continue to have reflux symptoms despite PPIs; symptom control and surveillance are separate conversations.